4//SEC Filing
Loven Jakob 4
Accession 0001209191-20-055041
CIK 0001741830other
Filed
Oct 15, 8:00 PM ET
Accepted
Oct 16, 3:49 PM ET
Size
12.2 KB
Accession
0001209191-20-055041
Insider Transaction Report
Form 4
Kronos Bio, Inc.KRON
Loven Jakob
Director
Transactions
- Conversion
Series A Preferred Stock
2020-10-14−1,304,563→ 0 total(indirect: See footnote)→ Common Stock (1,376,313 underlying) - Conversion
Convertible Promissory Note
2020-10-14→ 0 total(indirect: See footnote)Exercise: $16.15Exp: 2022-02-20→ Common Stock (169,031 underlying) - Conversion
Common Stock
2020-10-14+1,376,313→ 1,376,313 total(indirect: See footnote) - Conversion
Common Stock
2020-10-14$16.15/sh+169,031$2,729,851→ 1,545,344 total(indirect: See footnote)
Footnotes (3)
- [F1]Each share of Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
- [F2]The securities are held by Nextech V Oncology S.C.S, SICA-SIF ("Nextech V"). The reporting person currently serves as a member of the leadership team at Nextech Invest AG ("Nextech AG"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
- [F3]The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering.
Documents
Issuer
Kronos Bio, Inc.
CIK 0001741830
Entity typeother
Related Parties
1- filerCIK 0001753644
Filing Metadata
- Form type
- 4
- Filed
- Oct 15, 8:00 PM ET
- Accepted
- Oct 16, 3:49 PM ET
- Size
- 12.2 KB